<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">66501</article-id><article-id pub-id-type="doi">10.7554/eLife.66501</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Ubiquitination and degradation of NF90 by Tim-3 inhibits antiviral innate immunity</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-223600"><name><surname>Dou</surname><given-names>Shuaijie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223601"><name><surname>Li</surname><given-names>Guoxian</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223602"><name><surname>Li</surname><given-names>Ge</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223603"><name><surname>Hou</surname><given-names>Chunmei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223611"><name><surname>Zheng</surname><given-names>Yang</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223605"><name><surname>Tang</surname><given-names>Lili</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223606"><name><surname>Gao</surname><given-names>Yang</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223607"><name><surname>Mo</surname><given-names>Rongliang</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223608"><name><surname>Li</surname><given-names>Yuxiang</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-39643"><name><surname>Wang</surname><given-names>Renxi</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223609"><name><surname>Shen</surname><given-names>Beifen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-223610"><name><surname>Zhang</surname><given-names>Jun</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-221795"><name><surname>Han</surname><given-names>Gencheng</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1408-878X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor3">*</xref><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Immunology</institution>, <institution>Beijing Institute of Basic and Medical Sciences</institution>, <addr-line><named-content content-type="city">Beijing</named-content></addr-line>, <country>China</country></aff><aff id="aff2"><institution content-type="dept">4.Department of Oncology,</institution>, <institution>First hospital of Jilin University</institution>, <addr-line><named-content content-type="city">Department of Oncology,</named-content></addr-line>, <country>China</country></aff><aff id="aff3"><institution content-type="dept">Laboratory of Immunology</institution>, <institution>Beijing Institute of Basic Medical Sciences</institution>, <addr-line><named-content content-type="city">Beijing</named-content></addr-line>, <country>China</country></aff><aff id="aff4"><institution content-type="dept">Institute of Immunology,</institution>, <institution>Medical School of Henan University,</institution>, <addr-line><named-content content-type="city">Kaifeng</named-content></addr-line>, <country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-62461"><name><surname>Schoggins</surname><given-names>John W</given-names></name><role>Reviewing editor</role><aff><institution>University of Texas Southwestern Medical Center</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>wang_renxi@hotmail.com</email> (RW);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>zhangjun@henu.edu.cn</email> (JZ);</corresp><corresp id="cor3"><label>*</label>For correspondence: <email>genchenghan@163.com</email> (GH);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>10</day><month>06</month><year>2021</year></pub-date><volume>10</volume><elocation-id>e66501</elocation-id><history><date date-type="received"><day>13</day><month>01</month><year>2021</year></date><date date-type="accepted"><day>08</day><month>06</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Dou et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Dou et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-66501-v1.pdf"/><abstract><p>Nuclear Factor 90 (NF90) is a novel virus sensor that serves to initiate antiviral innate immunity by triggering the stress granules (SGs) formation. However, the regulation of the NF90-SGs pathway remain largely unclear. We found that Tim-3, an immune checkpoint inhibitor, promotes the ubiquitination and degradation of NF90 and inhibits NF90-SGs mediated antiviral immunity. Vesicular Stomatitis Virus (VSV) infection induces the up-regulation and activation of Tim-3 in macrophages which in turn recruited the E3 ubiquitin ligase TRIM47 to the zinc finger domain of NF90 and initiated a proteasome-dependent degradation via K48-linked ubiquitination at Lys297. Targeted inactivation of the Tim-3 enhances the NF90 downstream SGs formation by selectively increasing the phosphorylation of PKR and eIF2a, the expression of SGs markers G3BP1 and TIA-1, and protected mice from VSV challenge. These findings provide insights into the crosstalk between Tim-3 and other receptors in antiviral innate immunity and its related clinical significance.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><funding-statement>This work was supported by the National Natural Sciences Foundation of China (grants no. 81971473, 81771684), and the Beijing Natural Sciences Foundation (grant no.7192145).</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: The protocol was approved by the Ethics Committee of Animal Experiments of the Beijing Institute of Brain Sciences（ (IACUC-DWZX-2018-645). All efforts were made to minimize suffering.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files.</p></sec><supplementary-material><ext-link xlink:href="elife-66501-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>